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Abstract
Objectives: Although intravenous immunoglobulin (IVIG) is highly effective in Kawasaki disease (KD), mechanisms
are not understood and 10-20% of patients are treatment-resistant, manifesting a higher rate of coronary artery
aneurysms. Murine models suggest that α2-6-linked sialic acid (α2-6Sia) content of IVIG is critical for suppressing
inflammation. However, pro-inflammatory states also up-regulate endogenous levels of β-galactoside:α2-6
sialyltransferase-I (ST6Gal-I), the enzyme that catalyzes addition of α2-6Sias to N-glycans. We asked whether IVIG
failures correlated with levels of α2-6Sia on infused IVIG or on the patient’s own endogenous IgG.
Methods: We quantified levels of α2-6Sia in infused IVIG and endogenous IgG from 10 IVIG-responsive and 10
resistant KD subjects using multiple approaches. Transcript levels of ST6GAL1, in patient whole blood and B cell
lines were evaluated by RT-PCR. Plasma soluble (s)ST6Gal-I levels were measured by ELISA.
Results: There was no consistent difference in median sialylation levels of infused IVIG between groups. However,
α2-6Sia levels in endogenous IgG, ST6GAL1 transcript levels, and ST6Gal-I protein in serum from IVIG-resistant KD
subjects were lower than in responsive subjects at both pre-treatment and one-year time points (p <0.001,
respectively).
Conclusions: Our data indicate sialylation levels of therapeutic IVIG are unrelated to treatment response in KD.
Rather, lower sialylation of endogenous IgG and lower blood levels of ST6GALI mRNA and ST6Gal-I enzyme predict
therapy resistance. These differences were stable over time, suggesting a genetic basis. Because IVIG-resistance
increases risk of coronary artery aneurysms, our findings have important implications for the identification and
treatment of such individuals.
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Introduction
Kawasaki disease (KD) is an acute, self-limited vasculitis of
unknown etiology that predominantly affects infants and
children [1]. Coronary artery (CA) aneurysms, the most severe
complication, occur in 25% of untreated children and may lead
to ischemic heart disease, myocardial infarction, or sudden
death [2]. While a single high dose of intravenous
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immunoglobulin (IVIG) terminates the fever and acute
inflammation in most subjects and dramatically reduces the
incidence of CA aneurysms,10 to 20% of KD patients are IVIG-
resistant and have persistent or recrudescent fever at least 36
hours after the end of the initial IVIG infusion [3]. These
subjects are at higher risk of developing CA abnormalities [4].
Neither the anti-inflammatory mechanism of IVIG nor the cause
of IVIG-resistance is well understood.
Several mechanisms may account for the anti-inflammatory
activity of IVIG in different disease states [5-8]. IgG binds to
specific receptor molecules (FcγRs) through the Fc region with
the N-linked complex biantennary glycan (N-glycan), which can
be modified by specific carbohydrate moieties that have
profound effects on binding affinity (Figure 1A) [9]. IgG glycan
modifications such as addition of sialic acid (Sia), galactose
(Gal) or fucose, in serum IgG is associated with different
inflammatory and immune system diseases, including
rheumatoid arthritis and myasthenia gravis [10,11]. In mice, the
addition of Sia to the non-reducing end of the N-glycan in IVIG
leads to a reduction in systemic inflammation, although the
exact mechanism is controversial [12-18]. Sialylated Fc
structures are observed in 2 - 4% of IgG molecules in IVIG
pooled from healthy adults [12,19-21]. Although sialylation of
the penultimate Gal on the complex N-glycan can occur via
either α2-3 or α2-6 linkage, only the α2-6-linked sialic acid
(α2-6Sia) is associated with the anti-inflammatory effects of
IVIG (Figure 1B) [22,23].
β-Galactoside α2-6 sialyltransferase-I (ST6Gal-I) acting on
the Gal(β4)GlcNAc terminal structure of the biantennary N-
glycan of the Fc domain catalyzes the addition of α2-6Sias
(Figure 1B) [20]. Although the addition of α2-6Sias in IgG and
the expression of ST6Gal-I, is thought to be critical for in vivo
regulation of inflammation, none of these variant glycosylation
patterns of IgG has been implicated in treatment response in
KD [24-30]. Our first hypothesis was that IVIG preparations
given to IVIG-resistant KD patients have lower levels of
sialylation and thus limited anti-inflammatory effect. The
second hypothesis was that IVIG-resistant KD patients have
lower levels of sialylated endogenous IgG compared to IVIG-
responsive patients. To investigate the mechanism of IVIG-
response in KD patients, we measured levels of α2-6Sias,
fucose, and Gal in IgG from IVIG-responsive and -resistant KD
subjects. Both transcript and protein levels of ST6Gal-I were
analyzed in whole blood and cell lysates from Epstein-Barr
virus (EBV)-transformed B cell lines established from IVIG-
responsive and -resistant subjects.
Materials and Methods
Subjects
We selected 20 children (10 IVIG-resistant patients and 10
age-matched IVIG-responders) who met American Heart
Association clinical criteria for complete or incomplete KD
during their acute illness from among the subjects enrolled in a
biobanking study [31]. All KD subjects were initially treated with
IVIG (2 g/kg) and aspirin (80 mg/kg/day) during the acute
phase. Clinical data included age, sex, illness day at diagnosis,
CA status, ethnicity, and pre-treatment laboratory values (Table
1). IVIG-resistance was defined as persistent or recrudescent
fever (T ≥38.0 °C rectally or orally) at least 36 hours after the
completion of the IVIG infusion.
Ten age-similar subjects with other rash-fever illnesses and
10 age-similar healthy children served as controls (Table 1).
Febrile control subjects were previously healthy children
recruited from Emergency Department at Rady Children’s
Hospital San Diego who had a self-limited illness with at least 3
days of fever and at least one of the clinical signs of KD (rash,
conjunctival injection, cervical lymphadenopathy, erythematous
oral mucosa, and erythematous or edematous hands or feet)
and were diagnosed as self-limited viral syndrome. Healthy
subjects were children undergoing minor elective surgery for
polydactyly.
Samples
Whole blood was collected from KD subjects before
treatment with IVIG and one year later and from febrile subjects
at the time of phlebotomy for diagnostic evaluation, and from
healthy subjects at the time of preoperative venous
cannulation. Serum was separated within 48 hours of collection
and stored at -70°C until samples were analyzed. RNA was
extracted using PAXgene blood miRNA kit (PreAnalytix,
QIAGEN, NV) from whole blood collected in PAXgene tubes
(Qiagen, Hilden, Germany). A 1 ml aliquot of IVIG administered
to each KD subject was also collected.
Purification of IgG
IgG from 500 μl of serum was isolated using a 0.2 mL NAbTM
protein A column (Thermo Scientific, MA) according to the
manufacturer’s instructions. Briefly, serum was diluted in
binding buffer (100 mM sodium phosphate containing 150 mM
NaCl, pH 7.2) and passed through the column. IgG was eluted
in 400 μl fractions using buffer (pH 2.8) provided into collection
tubes preloaded with 40 μL of 1 M Tris-HCl 1 M, pH 8.5 for
neutralization. IgG levels were measured using a NanoDrop®
ND-1000 Spectrophotometer (Thermo Scientific, MA).
Isolation of F(ab')2 and Fc fragments
After buffer was exchanged using Zeba™ Spin Desalting
Columns (Thermo Scientific, MA) to 20 mM sodium
phosphate/HCl containing 10 mM EDTA (pH 7.0), IgG samples
(250 μg) were incubated with 50% immobilized papain (Thermo
Scientific, MA) for 6 hours at 37 °C in 20 mM sodium
phosphate/HCl containing 10 mM EDTA (pH 7.0). Papain-
digested IgG was purified again using the NAbTM protein A
column as previously described. Specific cleavage of the hinge
region of IgG, releasing F(ab')2 and Fc fragments, was verified
by Western blot analysis.
Western blot analysis
Purified Fc and F(ab')2 fragments from IVIG, serum, or cell
lysates were resolved on 12% polyacrylamide gels (Bio-Rad,
CA) under reducing conditions using 98% 2-mercaptoethanol
(Bio-Rad, CA). After electrophoresis, proteins were transferred
onto PVDF (Bio-Rad, CA) membranes following standard
procedures. For Sia detection, blocking with a Carbo-Free™
IgG Sialylation and Kawasaki Disease
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Blocking Solution (Vector Laboratories, CA), followed by
incubation with either biotinylated Sambucus nigra agglutinin
(SNA) lectin (2 μg/ml, B-1305, Vector Laboratories,CA) for 2-6
SA or biotinylated Maackia amurensis lectin-II (MAL-II) (4
μg/ml, B-1265, Vector Laboratories, CA) for α2-3 Sia linkage,
followed by incubation with Streptavidin-Horseradish
peroxidase (HRP) (DY991, R&D systems, MN). For detection
of the Fc fragment of IgG or ST6Gal-I, membranes were
blocked with a 5% BSA solution followed by incubation with
primary antibodies (Mouse anti-human Fc antibody,1:5,000
dilution, MAB1304, Millipore, MA or Human ST6Gal-I antibody,
1:1:30,000 dilution, AF5924, R&D systems, MN) overnight at 4
°C, and detector antibodies (Sheep anti-mouse IgG ECL HRP-
linked antibody, 1: 50,000 dilution, NA931 GE Healthcare, NJ
or Biotinylated anti-rabbit IgG antibody:1:300,000dilution,
NA934,GE Health care, NJ) for 2 hours at room temperature,
followed by streptavidinHRP (R&D systems, MN) for 2 hours at
room temperature. Detection was performed using the ECL
Plus Western Blotting Detection Reagents (GE Health care,
NJ) and exposure to X-ray film.
To quantitate the fraction of α2-6Sias on infused IVIG (5% or
10% Gammagard Liquid, Baxter, IL) and endogenous IgG from
KD and control subjects, IgG was isolated using Protein A
columns from the IVIG preparation infused into each KD
Figure 1.  Structure of N-glycans in human IgG.  (A) N-glycan with attached monosaccharaides on IgG Fc region. The N-glycan
that is attached to the conserved asparagine (Asn) residue at position 297 in the Fc comprises a core structure of N-
acetylglucosamine and mannose, plus additional carbohydrate residues, which can vary, including fucose, galactose, sialic acid and
bisecting N-acetylglucosamine. (B) Scheme showing the described N-glycan in human IgG and activities of the enzymes studied in
this work. The arrows indicate the carbohydrate units added or hydrolyzed by the corresponding enzymes. The human glycans are
mainly classified as 'biantennary complex' structure with a core fucose and are often terminated with sialic acid. The third N-
acetylglucosamine (GlcNAc) bisecting arm represents around 10% of human IgGs glycoforms. Only the α2-6-linked sialic acid is
associated with the anti-inflammatory effects of IVIG. Black square, GlcNAc; white triangle, fucose; white circle, mannose; gray
circle, galactose; black diamond, α2-6 linkage sialic acid. ST6Gal-I: β-galactoside α2-6 sialyltransferase-1, Neu1: neuramidase 1,
β4GALT1: β1,4-galactosyltransferase 1, GLB1: β-galactosidase 1, FUT8: α1-6 fucosyltransferase , FUCA1:α-fucosidase.
doi: 10.1371/journal.pone.0081448.g001
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subject and from the serum of 10 IVIG-responsive and 10
resistant KD subjects at the acute (pre-treatment) and
convalescent (1 year after KD onset) time points, and from 10
age-similar febrile and 10 healthy control children (Table 1).
Median yields were 3.8 mg (IQR: 3.5-3.9 mg) and 1.9 mg
(1.5-2.3 mg) of IgG from 500 μl of IVIG and serum,
respectively. Following papain digestion, sodium dodecyl
sulfate polyacrylamide gel electrophoresis (SDS-PAGE)
showed Coomassie-stained bands of the expected sizes for Fc
(28 kDa) and F(ab')2 (25 kDa) (Figure S1A). Western blotting
for papain-digested IgG detected only α2-6Sias but not α2-3-
linked sialic acid (α2-3Sias) on the Fc portion of IgG (Figure
S2B). Neither α2-6Sias nor α2-3Sias was detected on the
F(ab')2 portion. Therefore, whole IgG was used in the following
assays to evaluate glycosylation of N-glycan on the Fc portion.
Glycosylation assays (Figure 2)
Release of N-glycan from purified IgG.  250 μg of IgG was
solubilized and denatured using denaturing buffer containing
0.5% Sodium Dodecyl Sulfate (SDS) and 2-Mercaptoethanol.
Fivefold excess NP-40 relative to SDS was added and the
reaction mixture was kept at room temperature for 1h. Then N-
glycans were released using PNGaseF from the denatured
IgG. The enzymatic digestion was done for 24h at 37 °C
incubator to ensure complete release of the N-glycans.
Released N-glycans were purified by passing the reaction
mixture over Sep-Pak C18 cartridge (Waters, MA) followed by
a porous graphitized carbon (PGC) cartridge (Thermo
Scientific, MA). Under aqueous conditions, oligosaccharides
bind to the PGC cartridge, while salts and buffers pass through.
N-glycans were then eluted with aqueous 30% acetonitrile
containing 0.1% Trifluoroacetic acid (TFA). Acetonitrile and
TFA were removed by lyophilization and purified N-glycans
were used for subsequent analyses.
Quantitation of Sia after flourophore tagging using the
reverse phase (RP) high-performance liquid
chromatography (HPLC).  N-glycans isolated from 10 μg IgG
were reacted with 2 M Acetic Acid at 80°C for 3 hours to
release Sia from N- glycans. The released Sias were purified
by ultrafiltration through a 3,000 dal Molecular weight cut-off
spin filter (Millipore, MA) and tagged with 1,2-diamino-4,5-
methylenedioxybenzene (DMB)-labeled Sia. The DMB-tagged
Sias were analyzed by RP-HPLC using C18 column (Acclaim
120, Thermo Scientific, MA, 4.6 x 250mm, 5um particle size)
with on-line fluorescence detection (Dionex RF2000, Dionex,
CA).
Monosaccharide analysis by the high performance anion
exchange chromatography with pulsed amperometric
detection (HPAEC-PAD).  N-glycans from 10 μg IgG were
treated with 200 μl of 2 M TFA at 100 °C for 4 hours to cleave
all glycosidic linkages. Acid was evaporated by dry nitrogen
flush and co-evaporation twice with 1:1 isopropanol to ensure
complete removal of acid. Finally, the samples were dissolved
in water and analyzed by HPAEC-PAD using a CarboPac PA-1
column (Dionex, CA). The monosaccharides from the N-
Table 1. Clinical characteristics and laboratory values at the acute time point for study subjects in glycosylation assays.
 KD subjects Control subjects
 IVIG-responsive (n=10) IVIG-resistant (n=10) p Febrile control (n=10) p** Healthy control (n=10) p**
Age at diagnosis, years 3.0 (2.3-3.2)* 2.3 (1.5-3.5) NS 2.3 (1.1-3.3) NS 2.4 (2.0-2.5) NS
Male, n (%) 7 (70) 3 (30) NS 8 (80) NS 7 (70) NS
***Illness day at sample collection, days 5.0 (5.0-6.0) 5.0 (4.3-6.8) NS 4.0 (2.3-6.0) NS NA  
Incomplete KD, n (%) 1 (10) 1 (10) NS NA  NA  
Coronary artery aneurysms, n (%) 2 (20) 2 (20) NS NA  NA  
Ethnicity, n        
Asian 2 3  1  0  
African-American 1 0  0  0  
Caucasian 2 0  1  5  
Hispanic 3 3  5  5  
More than race 2 4  3  0  
CRP, mg/dl 6.3 (5.1-12.7) 11.8 (6.5-20.1) NS 1.0 (2.2-2.4) < 0.001 NA  
ESR, mm/h 57 (50-76) 64 (52-74) NS 18 (10-31) < 0.001 NA  
WBC, ×103/mm3 10.5 (9.8-14.5) 14.5 (11.6-17.6) NS 9.5 (7.5-14.8) NS NA  
Absolute neutrophil count, cells/mm3 7683 (4504-9579) 10208 (8256-3653) NS 4670 (2738-8488) NS NA  
Platelet count, ×103/mm3 323 (266-530) 351 (300-415) NS 331 (256-357) NS NA  
ALT, IU/l 38 (23-66) 35 (30-103) NS 30 (18-38) NS NA  
GGT, IU/l 43 (21-70) 41 (26-81) NS 16 (14-21) 0.006 NA  
* Values are presented as median (IQR). p-values were calculated by Mann–Whitney U test for continuous variables and by Fisher’s exact tests for categorical variables.
** p-values are for comparisons between KD and control patients.
*** Illness day 1: first calendar day of fever.
KD: Kawasaki disease, IVIG: intravenous immunoglobulin, CRP: C-reactive protein (Normal range: <0.5 mg/dl) , ESR: erythrocyte sedimentation rate, WBC: white blood
count, ALT: alanine aminotransferase (Normal range: 10-25 IU/L), GGT: gamma-glutamyltransferase (Normal range: 10-22 IU/L), NA: Not applicable, NS: Not Significant.
doi: 10.1371/journal.pone.0081448.t001
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glycans were quantified using known quantities of authentic
monosaccharide standards.
2AB labeling of glycans.  The 2-AB was reductively
coupled with purified (I think it was mentioned in the scheme)
N-glycans with a free reducing end. In brief, 6.0 mg of 2-AB
reagent was dissolved in 200 μl of 35:65 glacial acetic acid:
DMSO mixture. The entire mixture was added to 6.5 mg of
sodium cyanoborohydride in a separate tube. The reaction
mixture was mixed thoroughly by vortexing and sonication. 10
μl of this tagging reagent was added to each sample and
incubated at 65 °C for 2.5 hours. After 2AB labeling, the
samples were purified by passing through over a Glycoclean S-
cartridge and dried on a Speed-vac before further analysis.
Per-O-methylation (PM) of glycans.  N-glycans from 200
μg IgG were dissolved in dry DMSO and stirred for one hour
until the sample was completely dissolved. Sodium hydroxide
slurry in DMSO was added as a reacting base followed by
addition of 200 μl of methyl iodide. The reaction mixture was
vigorously stirred for 1 hour followed by addition of another
aliquot of 100 μl of methyl iodide with continued stirring for
additional 30 minutes. The reaction was stopped by adding 1
ml of ice-cold MilliQ-water followed by addition of 1 ml of
chloroform. The reaction mixture was then vortexed and
centrifuged at 2000 rpm for 2 minutes to separate the
chloroform and aqueous layers. The aqueous layer was
discarded and the chloroform layer was washed three times
with 1 ml of water. The chloroform layer containing the partially
methylated glycans was then dried and used for further
analysis by the matrix-assisted laser desorption-ionization time-
of-flight mass spectrometry (MALDI-TOF MS) or as partially
methylated alditol acetate (PMAA) derivative for linkage
analysis by the gas chromatography-mass spectrometry.
MALDI-TOF MS profiling of glycans.  Permethylated
glycans were dissolved in 20 ul of absolute methanol and
mixed with SDHB matrix in a 1:1 ratio and spotted onto the
MALDI plate. The samples were air-dried and analyzed in
positive reflectron mode.
PMAA.  The PM samples were hydrolyzed by 4N TFA at 100
°C for 4 hours and acid was removed by co-evaporation using
1:1 isopropanol: water (v/v) mixture under dry nitrogen flush
followed by removal of the acid using a dry nitrogen flush. The
acid was removed completely by coevaporation twice using 1:1
isopropanol: water mixture under dry nitrogen flush. Hydrolyzed
samples were reduced overnight at room temperature using
sodium borodeuteride in 1 M ammonium hydroxide solution.
Excess reducing agent was neutralized on an ice bath by
slowly adding ice-cold 30% acetic acid. The boric acid thus
formed was removed by repeated co-evaporation using 200 μl
of acidified methanol thrice and absolute methanol thrice
sequentially. Dried samples were stored on a vacuum
Figure 2.  Overview of different glycosylation assays.  PNGase F: peptide -N-Glycosidase F, DMB assay: 1,2-diamino-4,5-
methylenoxybenzene (DMB)-labeled sialic acid by HPLC, 2AB: 2-aminobenzamide, PM: per-O-methylation, MALDI-TOF: matrix-
assisted laser desorption-ionization time-of-flight. PMAA: partially methylated alditol acetate, GC-MS: gas chromatography–mass
spectrometry, HPAEC-PAD: high performance anion exchange chromatography with pulsed amperometric detection.
doi: 10.1371/journal.pone.0081448.g002
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desiccator on over P2O5 as desiccant for two hours and finally
treated with 1:1 acetic anhydride: pyridine mixture at 100 °C for
1hour. Unreacted pyridine and acetic anhydride was removed
by nitrogen flush and PMAA samples were dissolved in
dichloromethane and injected in the gas chromatography-mass
spectrometry (GC-MS).
GC-MS analysis of PMAA derivative (linkage
analysis).  PMAA analysis was done by GC-MS using
Restek-5 ms capillary column (30 m x 0.25 mm l x i.d., Restek,
PA). Identification was achieved by using a combination of
retention times (as compared to those of known standards
analyzed under the same conditions) and mass fragmentation
pattern. The results were shown by the ratio of the amounts of
6-linked Gal and inositol as the 6-linked Gal indicates the
binding site of α2-6Sias.
Microarray Analysis of ST6GAL1
Two different microarray platforms (Illmina array and
Affymetrix Human Genome U133 Plus 2.0 Array) were used to
study two independent cohorts of KD subjects and the data
were mined for the purpose of this study [32]. On the Illumina
microarray, we analyzed whole blood transcript levels from 110
IVIG-responsive and 30 IVIG-resistant mixed ethnicity subjects
at the acute (pre-treatment) and convalescent (at least three
weeks after treatment) time points. The dataset was then
normalized using quartile normalization procedure using
PreprocessCore package for R. Finally log 2 transformation
was performed. On the Affymetrix microarray we analyzed six
IVIG-responsive and six -resistant Japanese subjects at the
acute and convalescent (36 hours after end of treatment) time
points [32].
Quantitative (q)RT-PCR assay of ST6GAL1
To validate the microarray data, we performed qRT-PCR for
ST6GAL1 using whole blood RNA from the cohort of 20 KD
subjects (10 IVIG-responsive and 10 -resistant subjects) whose
IgG sialylation levels had been previously measured (Table 1).
We evaluated ST6GAL1 transcript levels using four primers for
the conserved region (Exon VI), Transcript 1-specific region
(P1 promoter region on Exon I, highly expressed on
hepatocytes), Transcript 2-specific region (Exon X-I region,
highly expressed in mature B-cells, kidney, and spleen) and
Transcript 3-specific region (Exon Y-Z region, expressed in
many different cells) on ST6GAL1 mRNA (Figure S2) [33,34].
Twenty KD subjects with paired samples (acute and 1 year
after onset) and 10 febrile control (viral syndrome) samples,
whose IgG has been analyzed for sialylation, were analyzed for
ST6GAL1 transcription levels. qRT-PCR was performed as
previously described using commercially available Taqman
primers for ST6GAL1 (conserved: Hs00949383_m1;
transcript1: AILJJB5; transcript 2: AI6RN2A; and transcript 3:
Hs00415704_m1, TaqMan, Life Technologies, NY) and primers
designed to detect specifically transcript 1 and 2; transcript 1:
(forward primer: 5′-CTGTCTCTTATTTTTTGCCTTTGCAG-3′,
reverse primer: 5′-TCCATGGGAGGGAAGGTTTATT-3′; probe:
5′-ATCCTGAGAAAAATGG-3′), and transcript 2 (forward
primer: 5′-TCTGCAGCATCCTTGATGATAAA-3′, reverse
primer: 5′-GCCAAGGCCCATTTTTCTC-3′, probe: 5′-
AATATGAGTTTTGATCATCC-3′) [35]. Relative abundance of
the target transcripts was normalized to the expression level of
the housekeeping gene, TATA box-binding protein-associated
factor, RNA polymerase I, B (TAF1B) (Hs01057259-m1,
Applied Biosystems), as previously described [36].
Isolation of B cells from subjects and incubation of
EBV- transformed B cell lines
Peripheral blood mononuclear cells (PBMC) were isolated
from heparinized blood samples by gradient centrifugation with
Ficoll Hypaque (Sigma-Aldrich, MO). B cell lines were created
by infecting PBMC with supernatant from an EBV-producing
marmoset-derived cell line B95-8 (American Type Culture
Collection, VA) and expanded in complete RPMI supplemented
with 10% fetal calf serum (HyClone Laboratories, UT).
Cell lysis
Cells were harvested and lysed in 300 mM NaCl, 50 mM
Tris, pH 7.4 contain 0.5 % Triton X-100 and cOmplete anti-
protease cocktail (Roche, Basel). Protein concentrations were
quantified using the NanoDrop® ND-1000 Spectrophotometer
(Thermo Scientific, MA).
ELISA assay for ST6Gal-I
ST6Gal-I in cell lysates, culture supernatants, serum, and
plasma were measured using the human ST6Gal-I ELISA Kit
(MyBioSource, CA) according to the manufacturer’s
instructions.
Statistical analysis
Data were analyzed using GraphPad Prism (GraphPad
Software, Inc., La Jolla, CA) software, and presented as
medians and IQR for continuous variables and frequency
counts and percentages for categorical variables. Univariate
analysis was performed with Fisher’s exact tests for categorical
variables and Wilcoxon rank sum tests for continuous
variables. Paired data for acute and convalescent samples
were analyzed using a Wilcoxon signed rank test. A p-value <
0.05 was considered significant.
Study approval
The Human Research Protection Program of the University
of California, San Diego approved this research protocol and
written informed consent was obtained from the parents of all
subjects and adolescent or child assent was obtained as
appropriate. The study protocol conforms to the ethical
guidelines of the 1975 Declaration of Helsinki.
Results
Sialylation of endogenous IgG and infused IVIG
Sia levels in endogenous IgG from IVIG-responsive and -
resistant KD and control subjects were measured using three
complementary techniques (Figure 2). We first quantified the
levels of total Sia using a semi-quantitative analysis of 1,2-
diamino-4,5-methylenedioxybenzene (DMB)-labeled Sia with
the reverse phase (RP) high-performance liquid
IgG Sialylation and Kawasaki Disease
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chromatography (HPLC) (Figure 3A and Table S1). Total Sia
levels in endogenous IgG were significantly lower in IVIG-
resistant KD subjects than in IVIG-responsive KD subjects at
the acute and one-year time points (Acute: p <0.001, and one-
year: p =0.014). Total Sia levels in endogenous IgG from IVIG-
responsive KD subjects were significantly higher during the
acute phase than at one year after KD onset, which we
presumed to represent their healthy baseline levels (p =0.002).
In contrast, the total Sia levels on endogenous IgG from IVIG-
resistant subjects were equally low at the acute and one year
time points.
As a second approach, levels of different glycan structures,
including sialylated N-glycans, released from IgG were
analyzed using the 2-aminobenzamide (2AB) labeling assay
(Figure 3B and Table S1). In keeping with the results from the
DMB assay, the levels of sialylated N-glycans in endogenous
IgG from IVIG-resistant subjects were significantly lower than
those in IVIG-responsive subjects at both the acute and one
year time points (Acute: p =0.002, and one-year: p =0.039).
Structural analysis by the 2AB assay was validated by the
matrix-assisted laser desorption-ionization time-of-flight mass
spectrometry (MALDI-TOF MS) analysis of per-methylated N-
glycans (Figure S3).
The third approach quantified the levels of α2-6Sias in
endogenous IgG from IVIG-responsive and -resistant KD
subjects by the gas chromatography-mass spectrometry (GC-
MS) (Figure 3C and Table S1). Consistent with previous
results, IVIG-responsive subjects had significantly higher
Figure 3.  Levels of sialic acid, fucose, and galactose in infused IVIG and endogenous IgG from IVIG-responsive and -
resistant KD subjects at acute and 1 year time points using four different assays.  (A) Levels of total sialic acid in IVIG and
endogenous IgG, measured by DMB assay, (B) Levels of sialylated N-glycans in IVIG and endogenous IgG, measured by 2AB-
labeling assay, (C) Levels of α2-6 linked sialic acid relative to 5 μg inositol in IVIG and endogenous IgG measured by GC-MS assay.
(D) Galactose levels on IVIG and endogenous IgG measured by HPAEC-PAD assay. (E) Fucose levels on IVIG and endogenous
IgG measured by HPAEC-PAD assay. The same subjects were used for all assays. Open symbols: Subjects with coronary
aneurysms. Results shown as medians and IQR. p-values by Mann-Whitney U test. *p<0.05, **p<0.01, ***p<0.001. IVIG:
intravenous immunoglobulin, KD: Kawasaki disease, DMB assay: 1,2-diamino-4,5-methylenoxybenzene (DMB)-labeled sialic acid
by HPLC, 2AB: 2-aminobenzamide, GC-MS: gas chromatography–mass spectrometry. HPAEC-PAD: high performance anion
exchange chromatography with pulsed amperometric detection.
doi: 10.1371/journal.pone.0081448.g003
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α2-6Sias compared to IVIG-resistant subjects at both the acute
and one-year time points (p <0.001, respectively) and had
higher levels during the acute phase compared to one year
later (p =0.014).
Thus, the three analyses above consistently demonstrated
significant differences between endogenous IgG from IVIG-
responsive and -resistant subjects irrespective of time points
tested. No relationship was found between Sia levels and the
occurrence of CA aneurysms in any of the three assays. All
three assays demonstrated higher Sia levels in endogenous
IgG in IVIG-responsive subjects (Figure 3A-C).
Sia levels in therapeutic IVIG were also assessed using
these three methodologies. Only the assay for sialylated N-
glycans showed a difference in the levels between IVIG
administered to responsive compared to resistant subjects (p
=0.019) (Figure 3A-C and Table S1). As expected, the levels of
Sia in the infused IVIG were significantly lower in all three
analyses compared to the endogenous IgG from KD subjects.
Terminal galactose and fucose in endogenous IgG and
infused IVIG
Levels of Gal in endogenous IgG from IVIG-resistant
subjects were significantly higher than in IVIG-responsive
subjects at the acute and one-year time points (Acute: p
=0.004, and 1 year: p =0.016) (Figure 3D). Total Gal levels on
infused IVIG, quantified by high performance anion exchange
chromatography with pulsed amperometric detection (HPAEC-
PAD), were also significantly higher in IVIG-resistant subjects
compared to IVIG-responsive subjects (median 1.6 and 2.1 ng/
μg IgG for IVIG-responsive and -resistant subjects,
respectively, p =0.048).
The HPAEC-PAD assay revealed no significant differences
in total fucose in infused IVIG or endogenous IgG, between
IVIG-responsive and -resistant subjects at either time point.
However, endogenous IgG fucose levels were higher among
IVIG-resistant KD subjects compared to febrile controls acutely
(p =0.014) and higher among IVIG-responsive and -resistant
KD subjects compared to healthy control subjects at the one-
year time point (IVIG-responsive: p =0.008, and -resistant
subjects: p =0.004) (Figure 3E).
Microarray analysis of transcript levels of glycosylation
enzymes
To assess the role of enzymes in glycosylation, we analyzed
the transcript levels of enzymes involved in α2-6-linked
sialylation, galactosylation, and fucosylation including
ST6GAL1 and neuraminidase 1 (NEU1) for sialic acid, β1-4
galactosyltransferase-I (B4GALT1) and β-galactosidase-I
(GLB1) for Gal, and α1-6 fucosyltransferase (FUT8) and α-
fucosidase (FUCA1) for fucose, by making use of our KD cDNA
microarray datasets reported previously (Table 2 and Figure
1B)[32].
Because the convalescent RNA samples were obtained at a
point in time when the subjects were completely healthy, we
assumed that the convalescent transcript levels represented
the subject’s normal baseline. Of the 6 enzymes on the arrays,
Table 2. Transcript levels of glycosylation enzymes in microarray data sets on different platforms.
   Acute/Convalescent IVIG-responsive /-resistant subjects at each time point
    Acute  Convalescent  
Array Symbol Probe ID Fold-differencep Fold- difference p Fold-difference p
Illumina (n: 110 IVIG-responsive, 30 IVIG-resistant
subjects) ST6GAL1 1260601 0.62 < 0.001 1.43 0.002 1.36 0.004
  1710630 0.77 < 0.001 1.06 NS 0.98 NS
 NEU1 4200692 1.76 < 0.001 0.93 NS 1.13 NS
 B4GALT1 3460386 1.11 < 0.001 0.91 0.024 0.92 NS
 GLB1 1340634 1.37 < 0.001 1.10 NS 0.94 NS
  4560064 1.43 < 0.001 1.04 NS 0.63 NS
 FUT8 3870497 0.77 < 0.001 1.29 NS 0.95 NS
 FUCA1 2060121 1.04 NS 0.96 NS 0.92 NS
Affymetrix (n: 6 IVIG-responsive, 6 IVIG-resistant
subjects) ST6GAL1 201998_at 0.56 0.025 1.95 0.009 1.69 0.015
 NEU1 208926_at 1.32 0.031 0.74 NS 0.59 NS
 B4GALT1 201883_s_at 1.01 NS 1.14 NS 0.86 NS
  228498_at 1.26 NS 0.73 NS 0.79 NS
  238987_at 0.99 NS 0.90 NS 0.87 NS
 GLB1 201576_at 1.16 NS 1.02 NS -1.04 NS
 FUT8 1554930_a_at 0.59 NS 0.85 NS 0.82 NS
  203988_s_at 0.64 NS 0.92 NS 0.65 NS
 FUCA1 202838_at　 0.66 NS 1.10 NS 1.33 0.023
Nominal p-values were calculated by Mann–Whitney U test. NS: Not Significant. ST6GAL1: β-galactoside alpha-2,6-sialyltransferase 1, NEU1: neuraminidase 1, B4GALT1:
β-1,4-galactosyltransferase 1, GLB1: β-galactosidase 1, FUT8: α-(1,6)-fucosyltransferase, FUCA1: α-fucosidase
doi: 10.1371/journal.pone.0081448.t002
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all except FUCA1 were differentially expressed at acute and
convalescent time points (Table 2).
A probe from the conserved exon VI of ST6GAL1 from the
Illumina array showed significantly lower transcript levels in
IVIG-resistant subjects compared to IVIG-responsive subjects
at both the acute and convalescent time points (Acute: p =
0.002, and Convalescent: p = 0.004) (Figure 4A and Table 2).
On the Affymetrix array, the transcript levels of ST6GAL1 from
exon VI in IVIG-resistant subjects were also significantly lower
than in IVIG-responsive subjects at both time points (Acute: p =
0.009, and Convalescent: p = 0.015) (Figure 4B and Table 2).
Transcript levels for NEU1 were up-regulated in all acute KD
subjects compared to the convalescent time point (Illumina: p
<0.001, Affymetrix: p =0.031). No differences were seen for
NEU1 between IVIG-responsive and -resistant KD subjects on
these platforms.
Because there were significant differences in IgG
fucosylation between KD and healthy control subjects, we
analyzed FUT8 and FUCA1 transcript levels. The only
significant difference was between the responsive and resistant
subjects at the convalescent time point (Illumina: p <0.001)
(Table 2).
Differential expression of ST6GAL1 by qRT-PCR
We evaluated ST6GAL1 transcript levels using four different
primer pairs corresponding to a conserved region (Exons V-VI)
and three unique transcripts: Transcript 1-specific region (Exon
I, highly expressed in hepatocytes), Transcript 2-specific region
(Exons X-I, expressed in mature B-cells, kidney and spleen)
and Transcript 3-specific region (Exons Y-Z region, expressed
in many different cells) Figure S2) [33,34]. The transcript levels
of the conserved region and Transcript 2 (mature B cell-
specific) were significantly lower in IVIG-resistant compared to
IVIG-responsive subjects at both the acute and 1 year time
points (Figure 5A and C). ST6GAL1 Transcript 1, which is
initiated by the P1 promoter in hepatocytes, was significantly
lower in IVIG-resistant subjects only at the one-year time point
(p =0.034) (Figure 5B). ST6GAL1 Transcript 3 levels were low
in all groups tested (p =0.043) (Figure 5D). No correlation was
observed between α2-6Sias levels on endogenous IgG and
ST6GAL1 transcript abundance levels (Figure S4). These
results suggest that the difference between IVIG-responsive
and resistant subjects was due to reduced levels of ST6GAL1
Transcript 2, which is transcribed specifically in B cells, kidney,
and spleen [34].
ST6GAL1 transcript and protein levels in B cell lines
We measured ST6GAL1 transcript levels in cell lysates from
B-cell lines from six IVIG-responsive and six resistant acute KD
subjects for whom lines were available (Table S2). Levels of
transcripts containing the conserved region in exon VI and
Transcript 2 were significantly lower in IVIG-resistant subjects
compared to responsive subjects (Figure 6A and C). Transcript
1 levels were not significantly different (Figure 6B). Soluble
(s)ST6Gal-I was present at low levels in the supernatant of B
cell lines from the three IVIG-responsive subjects, while none
was detected in the supernatants from resistant subjects
(Figure S5).
Figure 4.  Microarray analysis of ST6GAL1 transcript.  (A) Illumina array (probe ID: 1260601). On this microarray, whole blood
transcript levels from 110 IVIG-responsive and 30 IVIG-resistant subjects at the acute (pre-treatment) and convalescent (at least 3
weeks after treatment) time points were analyzed. (B) Affymetrix Human Genome U133 Plus 2.0 Array (probe ID: 201998_at),
whole blood transcript levels from six IVIG-responsive and six -resistant subjects (all Japanese) at the acute and convalescent (36
hours after end of treatment) time points were analyzed. Microarray clones were from exon VI (conserved region) of ST6GAL1
mRNA. Open symbols: Subjects with coronary aneurysms. Results shown as medians and IQR. p-values by Mann-Whitney U test.
*p<0.05, **p<0.01, ***p<0.001. KD: Kawasaki disease.
doi: 10.1371/journal.pone.0081448.g004
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Soluble ST6Gal-I in blood
Among the 20 KD subjects whose pre-treatment IgG
sialylation was measured, serum sST6Gal-I levels of were
significantly lower in IVIG-resistant subjects and febrile controls
compared to IVIG-responsive subjects (p =0.013) (Figure 7A).
However, no correlation was observed between sST6Gal-I
levels and ST6GAL1 transcript levels in whole blood from KD
subjects (data not shown). Using independent KD and febrile
control cohorts (Table S3), IVIG-resistant subjects had
Figure 5.  Whole blood transcript levels of ST6GAL1 in KD patients using qRT-PCR.  Transcript levels of ST6GAL1 were
analyzed with 4 different primer pairs. (A) Total ST6GAL1 transcript levels amplified with primers for conserved region spanning
exons V and VI, (B) ST6GAL1 Transcript 1 levels encoded by the P1 promoter (hepatocytes). (C) ST6GAL1 Transcript 2 levels
amplified with primer encoding exons X and I (B cells) (D) ST6GAL1 Transcript 3 levels encoding exons Y and Z (all cells). Results
are relative units of ST6GAL1 transcripts normalized for expression of housekeeping gene, TAF1B. Open symbols: Subjects with
coronary aneurysms. Bars are medians and IQR. p-values by Mann-Whitney U test. *p<0.05, **p<0.01, ***p<0.001. KD: Kawasaki
disease.
doi: 10.1371/journal.pone.0081448.g005
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significantly lower plasma sST6Gal-I levels compared to IVIG-
responsive subjects(p =0.025) (Figure 7B). sST6Gal-I levels
did not distinguish the seven KD subjects with CA aneurysms
from those with normal CA.
Discussion
In the first study to examine glycosylation patterns on
endogenous IgG and infused IVIG in KD subjects, we found a
consistent relationship between levels of sialic acid on
endogenous IgG and response to treatment, with lower levels
found in IVIG-resistant subjects (Figure 3A-C). Furthermore,
whole blood and B-cell line transcript levels and serum and
plasma levels of sST6Gal-I, the enzyme responsible for adding
the terminal sialic acid into the N-glycan structure of the Fc
region, were significantly lower in IVIG-resistant subjects
(Figure 4-7). This finding persisted at one year and suggests a
genetic difference in ST6Gal-I activity among children with
Figure 6.  Expression transcript levels of ST6GAL1 in EBV-transformed B cell lines from IVIG-responsive and -resistant KD
subjects at acute phase by qRT-PCR.  (A) Amplification with primers for the conserved region in exon VI in ST6GAL1 mRNA. (B)
Amplification with primers for Transcript 1 initiated from the P1 promoter in ST6GAL1 (P1 promoter and exon I region). (C)
Amplification with primers for Transcript 2 (exon X and I region) in ST6GAL1. qRT-PCR results are presented as relative units of
ST6GAL1 amplicon normalized for the housekeeping gene TAF1B. Open symbols: Subjects with coronary aneurysms. Results are
shown as medians and IQR. p-values by Mann-Whitney U test. *p<0.05. KD: Kawasaki disease.
doi: 10.1371/journal.pone.0081448.g006
Figure 7.  Soluble (s)ST6Gal-I in KD and febrile control subjects measured by ELISA assay.  (A) sST6Gal-I in serum from
IVIG-responsive and IVIG-resistant KD subjects and febrile controls. (B) sST6Gal-I levels in plasma from independent cohort of
IVIG-responsive and IVIG-resistant KD subjects and febrile controls. Open symbols: Subjects with coronary aneurysms. Results
shown as medians and IQR. p-values by Mann-Whitney U test. *p<0.05, **p<0.01, ***p<0.001. KD: Kawasaki disease.
doi: 10.1371/journal.pone.0081448.g007
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acute KD resistant to IVIG. In contrast, the low levels of
α2-6Sias in the infused IVIG did not appear related to the
subject’s response to IVIG therapy.
The glycans that decorate ligands and receptors play a
critical role in modulation of the immune response. The N-
linked oligosaccharide in the IgG Fc region maintains the steric
structure of the two heavy chains in an open confirmation that
is required for interaction with FcγRs expressed on different
populations of immune cells, and removal of this glycan alters
IgG binding affinity to FcγRs (Figure 1A) [37,38]. Significant
structural heterogeneity exists for the glycan profiles and
composition in healthy adult populations, including the addition
of fucose to the N-acetylglucosamine (GlcNAc) at the reducing
ends, the addition of GlcNAc to the mannose between the
binatennary structures (bisecting GlcNAc), or the addition of
Gal and sialic acid at the non-reducing ends of the biantennary
structure (Figure 1B) [19,39]. Human IgG Fc regions with a
sialylated, galactosylated, or fucosylated glycan have reduced
affinities for FcγRs compared with asialylalted, agalactosylated,
afucosylated Fc regions [40-44].
In this study, we confined our analysis to the sialylation of
IgG. The negative charge of terminal sialic acid can alter
protein function, affecting the binding and transport of ions and
stabilizing the conformation of many proteins including
enzymes [45]. Sialic acids in oligosaccharides regulate the
affinity of receptors for these ligands and modulate processes
involved in transmembrane signaling, fertilization, growth and
differentiation [46]. Some research reports suggest that
sialylated IgG induces anti-inflammatory signaling in immune
cells via specific lectins such as the C-type lectin dendritic cell-
specific intercellular adhesion molecule-3-grabbing non-integrin
(DC-SIGN), CD22/siglec-2, and CD23, although this remains
controversial [15-18,47-49]. The reduced endogenous IgG
sialylation in our IVIG-resistant subjects may have a direct
effect on their response to treatment, or may simply be a
marker for reduced ST6Gal-I activity. Thus, future research
should focus on sialylation of other proteins that may be
affecting treatment response.
In our study, sialic acid levels on the infused IVIG were low,
and only one of the three assays showed a lower level of sialic
acid on the IVIG received by IVIG-resistant subjects (Figure
3A-C). However, in mice, administration of hyper-sialylated
IVIG prevented arthritis at a ten-fold lower dose compared to
unsialylated IVIG [12]. Based on our data, there does not
appear to be a relationship between sialylation of IVIG and
treatment response in our human KD patients.
Gal and fucose modification of N-glycans on IgG are known
to be important in the modulation of inflammation in murine
models and human disease [10,40,43,44,50]. Levels of
galactosylated IgG in KD were significantly higher in IVIG-
resistant subjects compared to IVIG-responsive subjects at
both the acute and one-year time points (Figure 3D), which is
the opposite of what was seen for sialic acid, as expected..
Total Gal levels were much higher than sialic acid levels, which
suggests that only a minority of the terminal Gal molecules
were sialylated. Galactosylation plays a role in complement
activation by masking the terminal GlcNAc that binds to
mannose-binding lectin (MBL), a first step in complement
activation [10]. However, the role of complement in KD
pathogenesis is uncertain so the significance of increased
galactosylation in IVIG-resistant subjects it is unclear. The role
of fucose in immune regulation is demonstrated by the 100-fold
increase in affinity of the activating FcγRIIIA on NK cells and
IIIb on neutrophils for all classes of human IgG following
removal of the core fucose residue from the N-glycan in the
IgG Fc region [43,51-53]. We found no significant differences in
the levels of IgG fucosylation between KD subjects at the one-
year time point and healthy control subjects and between acute
KD subjects and febrile control subjects (Figure 3E). Therefore,
fucosylation of IgG does not appear to play a major role in KD
pathogenesis or response to therapy.
The predominant sialic acid linkage in human IgG Fc glycans
is α2-6 linkage, although Sia can also be found in a α2-3
linkage to the penultimate Gal on the Fc [13,22,42]. Using
Western blotting, we detected only α2-6-linked, and not α2-3
linked Sias on the Fc glycan of infused IVIG and endogenous
IgG from KD subjects. In addition, α2-6Sia was detected only
from the Fc, and not the F(ab')2 portion of the IgG molecule
(Figure S1B) . Our GC-MS measurement of α2-6Sias was
consistent with the low α2-6Sia levels in IVIG-resistant subjects
measured in the DMB and 2AB assays (Figure 3A-C). Although
the majority of the N-glycans have been detected on the Fc
region of IgG from healthy human sera [19,54], 15-20% of
human IgG molecules contain sialylated glycans on the F(ab')2
variable regions [55,56]. In addition, glycans in the F(ab')2
region are enriched for the bisecting GlcNAc compared to
those in the Fc region (Figure 1B) [57,58]. Using the MALDI-
TOF MAS technique, we detected bisecting GlcNAc in very few
IgG samples from KD and control subjects as well as other
minor structures from the F(ab')2 region (e.g. high mannose
structures). However, the signal intensities for this type of N-
glycan were very low (Figure S3D-F). From these data, we
conclude that the majority of the sialic acids in our IgG samples
are derived from the N-glycan in the Fc region.
One possible explanation for the findings from our
glycosylation analyses would be a genetic difference in
sialylation enzymes between IVIG-responsive and -resistant
subjects. Specifically, the lower α2-6Sia levels in endogenous
IgG from IVIG-resistant subjects could be due to reduced
transfer of Sias to the terminal Gal or to increased activity of
enzymes that remove the terminal Sia from the N-glycans in
IgG molecules (Figure 1B). Expression levels of ST6GAL1
were associated with IVIG treatment response in KD subjects
(Figure 4, 5 and Table 2). The importance of ST6Gal-I in
humoral immunity is well-established in both mice and humans
[59-63]. Of the three known variants of human ST6GAL1
transcripts, Transcript 1 is highly expressed in human
hepatocytes, Transcript 2 is highly expressed in mature B cells,
kidney, and spleen, and Transcript 3, appears to be
ubiquitously expressed in various tissues (Figure S2)
[33,34,64-66]. In mice, ST6GAL1 transcribed from the
hepatocyte-specific P1 promoter (Transcript 1) is critical for Fc
sialylation of circulating IgG, even though Transcript 2 is
abundantly expressed in mature B cells [20]. Although ST6Gal-
I is usually found in the Golgi or plasma membrane, it can be
proteolytically processed to a soluble form found in circulation
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[33,67]. ST6Gal-I also has anti-inflammatory effects by
catalyzing sialylation of other molecules including receptors,
lectins, and cytokines [24,25,29,30]. Studies in ST6GAL1 P1
promoter knock-out mice have revealed an unexpected role of
ST6GAL1 Transcript 1 in regulating inflammation, with higher
neutrophil response and G-CSF levels in knock-out mice
following an intra-peritoneal inflammatory challenge [29]. G-
CSF is a known biomarker for IVIG-resistance in KD, and
elevated neutrophil counts are also associated with treatment
resistance [68,69]. These observations could potentially be
linked to the lower levels of ST6Gal-I that may lead to
increased levels of G-CSF and increased numbers of
circulating neutrophils in IVIG-resistant KD subjects.
Microarray results were validated by qRT-PCR in the same
subjects whose IgG sialylation had been measured.
Amplification with primers specific for Transcript 2 showed the
greatest difference in transcript levels. The levels of total
ST6Gal-I and Transcript 2 from whole blood and B cell lines
from IVIG-resistant subjects were consistently lower than those
of responsive subjects (Figure 5A, C, and 6A, C). However, the
expression levels of other ST6Gal-I transcripts varied to a
lesser extent among subject groups (Figure 5B, D, and Figure
5B). There were no significant differences in whole blood
transcript levels of the enzyme responsible for removing sialic
acid, NEU1, between IVIG-responsive and -resistant subjects.
The potential cellular sources of ST6Gal-I in human blood have
not been rigorously studied.
Polymorphisms in human ST6Gal-I are associated with
autoimmune and inflammatory conditions as well as
atherosclerotic coronary artery disease in adults [63,70]. The
persistently low levels of ST6Gal-I at one year in IVIG-resistant
subjects suggest a genetic predisposition to a pro-inflammatory
state influenced by variation in ST6GAL1 expression. We are
currently studying polymorphisms in ST6GAL1 in these IVIG-
resistant and –responsive subjects.
We recognize several strengths and limitations to our study.
In this first analysis of IgG glycosylation patterns in children
with KD and febrile and healthy children, we have discovered a
potential biological mechanism to explain differences in
response to IVIG treatment in KD subjects. We used three
different analyses including DMB for total sialic acid, GC-MS
for α2-6Sias, and 2AB for sialylated N-glycans. It was important
to analyze these structures using a variety of experimental
techniques with different assay principles to be confident of the
results. All three methods showed low levels of sialic acid in
endogenous IgG from IVIG-resistant KD subjects compared to
IVIG-responsive subjects at both the acute (pre-treatment) and
one-year time points. As blood volumes available from ill and
anemic infants and young children were necessarily limited, we
established B cell lines from these subjects as a surrogate for
circulating B cells. Significant differences remained between
IVIG-responsive and -resistant subjects. However, the
expression of ST6GAL1 may have been altered by EBV-
mediated transformation [71]. We did not analyze IgG
subclasses, whose distribution may vary with age and disease
state, and glycosylation patterns may vary among subclasses
[72]. The ability to generalize from our results is affected by the
small sample size. Our findings should be viewed as
hypothesis-generating and should be explored further in larger
cohorts. While we found reproducible differences in sialylation
of IgG and expression levels of ST6GAL1 between the two KD
study populations, further investigation will be required to
uncover the genetic basis for these differences.
We found lower levels of α2-6Sia on endogenous IgG and
lower ST6Gal-I levels in IVIG-resistant subjects at both the
acute and one-year time points. Because IVIG-resistant KD
patients have a higher rate of aneurysms, there is a clinical
need to identify these subjects prior to IVIG administration and
to target them with adjunctive treatment strategies [73,74].
Rapid assays for genotypes associated with reduced ST6Gal-I
expression or for ST6Gal-I enzyme levels or activity could
serve as clinically useful biomarkers for IVIG-resistance.
Supporting Information
Figure S1.  (A) SDS-PAGE and Coomassie Blue stain of 3 μg
IgG following papain digestion. Positive control: 3 μg purified
human Fc fragment. (B) Western blots detecting Fc fragment,
α2-6 linkage sialic acid and α2-3 linkage sialic on 3 μg IgG
using anti-human Fc antibody, Biotinylated Sambucus nigra
agglutinin (SNA) lectin, and Maackia amurensis lectin-II (MAL-
II), respectively. 3 μg purified human Fc fragment, human
albumin, and fetuin were used for negative and positive
controls. IVIG: intravenous immunoglobulin, KD: Kawasaki
disease.
(TIFF)
Figure S2.  Structure of ST6GAL1 mRNA. ST6GAL1 has
three different transcripts depending on promoter used in
different cell types. Microarray clones were from exon VI
(conserved region). Transcript levels of ST6GAL1 were
analyzed with 4 different primer pairs. Our microarray clones
were from exon VI (conserved region) of ST6GAL1 mRNA.
Designed amplification with primers for the conserved region in
exon VI, primer for Transcript 1 initiated from the P1 promoter
(P1 promoter and exon I region, highly expressed in liver),
primer for Transcript 2 (exon X and I region, highly expressed
in spleen, kidney, and mature B cells), and primer for
Transcript 3 (exons Y and Z, expressed in all cells).
(TIFF)
Figure S3.  Profiling N-glycans of infused IVIG and
endogenous IgG from IVIG-responsive KD patient by 2AB
labeling and MALDI-TOF assays. (A) 2AB labeling profiles of
given IVIG preparation (B) 2AB labeling profiles of endogenous
IgG from IVIG-responsive at acute (pre-treatment) phase. (C)
2AB labeling profiles of endogenous IgG from IVIG-responsive
at 1year phase after KD onset. (D) MALDI-TOF profiles of
given IVIG preparation (E) MALDI-TOF profiles of endogenous
IgG from IVIG-responsive at acute (pre-treatment) phase. (F)
MALDI-TOF profiles of endogenous IgG from IVIG-responsive
at 1year phase after KD onset. Blue square, GlcNAc; red
triangle, fucose; green circle, mannose; yellow circle,
galactose; purple diamond, α2-6 linkage sialic acid. All samples
analyzed by glycobiology assays were verified by MALDI-TOF
and 2AB assays. IVIG: intravenous immunoglobulin, KD:
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Kawasaki disease, 2AB: 2-aminobenzamide, MALDI-TOF:
matrix-assisted laser desorption-ionization time-of-flight.
(TIFF)
Figure S4.  Correlation between levels of ST6GAL1
transcript and 2-6SA in IgG Coefficient of correlation was
provided by the Speaman's correlations. (A) Correlation
between expression levels of total ST6GAL1 transcript (exon VI
region) and 2-6SA levels in IgG, (B) Correlation between
ST6GAL1 Transcript 2 (exon X and I region) and 2-6SA levels
in IgG.
(TIFF)
Figure S5.  Soluble ST6Gal-I in culture supernatants from
EBV-transformed B cell lines from 3 IVIG-responsive and 3
-resistant patients by ELISA assay. KD: Kawasaki disease.
(TIFF)
Table S1.  Glycosylation assays for measurement of sialic
acid in infused IVIG and endogenous IgG from IVIG-
responsive and -resistant KD subjects.
(DOC)
Table S2.  Characteristics of KD subjects for EBV-
transformed B cell line experiments.
(DOC)
Table S3.  Clinical characteristics and laboratory values at
the acute time point for study subjects for ST6GAL1
experiments.
(DOC)
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